Literature DB >> 27746185

Complement deposition induced by binding of anti-contactin-1 auto-antibodies is modified by immunoglobulins.

Luise Appeltshauser1, Andreas Weishaupt1, Claudia Sommer1, Kathrin Doppler2.   

Abstract

Inflammatory neuropathies associated with auto-antibodies against paranodal proteins like contactin-1 are reported to respond poorly to treatment with intravenous immunoglobulins (IVIG). A reason might be that IVIG interacts with the complement pathway and these auto-antibodies often belong to the IgG4 subclass that does not activate complement. However, some patients do show a response to IVIG, especially at the beginning of the disease. This corresponds with the finding of coexisting IgG subclasses IgG1, IgG2 and IgG3. We therefore aimed to investigate complement deposition and activation by samples of three patients with anti-contactin-1 IgG auto-antibodies of different subclasses as a potential predictor for response to IVIG. Complement deposition and activation was measured by cell binding and ELISA based assays, and the effect of IVIG on complement deposition was assessed by addition of different concentrations of IVIG. Binding of anti-contactin-1 auto-antibodies of all three patients induced complement deposition and activation with the strongest effect shown by the serum of a patient with predominance of IgG3 auto-antibodies. IVIG led to a reduction of complement deposition in a dose-dependent manner, but did not reduce binding of auto-antibodies to contactin-1. We conclude that complement deposition may contribute to the pathophysiology of anti-contactin-1 associated neuropathy, particularly in patients with predominance of the IgG3 subclass. The proportion of different auto-antibody subclasses may be a predictor for the response to IVIG in patients with auto-antibodies against paranodal proteins.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Auto-antibody; C1q; C3c; Complement; Contactin-1; ELISA; IVIG; IgG subclass; Inflammatory neuropathy

Mesh:

Substances:

Year:  2016        PMID: 27746185     DOI: 10.1016/j.expneurol.2016.10.006

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  11 in total

Review 1.  Immune-mediated neuropathies.

Authors:  Bernd C Kieseier; Emily K Mathey; Claudia Sommer; Hans-Peter Hartung
Journal:  Nat Rev Dis Primers       Date:  2018-10-11       Impact factor: 52.329

Review 2.  A New Classification System for IgG4 Autoantibodies.

Authors:  Inga Koneczny
Journal:  Front Immunol       Date:  2018-02-12       Impact factor: 7.561

3.  Anti-pan-neurofascin IgG3 as a marker of fulminant autoimmune neuropathy.

Authors:  Helena Stengel; Atay Vural; Anna-Michelle Brunder; Annika Heinius; Luise Appeltshauser; Bianca Fiebig; Florian Giese; Christian Dresel; Aikaterini Papagianni; Frank Birklein; Joachim Weis; Tessa Huchtemann; Christian Schmidt; Peter Körtvelyessy; Carmen Villmann; Edgar Meinl; Claudia Sommer; Frank Leypoldt; Kathrin Doppler
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2019-08-16

4.  Treatment response to cyclophosphamide, rituximab, and bortezomib in chronic immune-mediated sensorimotor neuropathies: a retrospective cohort study.

Authors:  Jeremias Motte; Anna Lena Fisse; Nuray Köse; Thomas Grüter; Hannah Mork; Diamantis Athanasopoulos; Miriam Fels; Susanne Otto; Ines Siglienti; Christiane Schneider-Gold; Kerstin Hellwig; Min-Suk Yoon; Ralf Gold; Kalliopi Pitarokoili
Journal:  Ther Adv Neurol Disord       Date:  2021-03-05       Impact factor: 6.570

Review 5.  Novel Immunological and Therapeutic Insights in Guillain-Barré Syndrome and CIDP.

Authors:  Luis Querol; Cinta Lleixà
Journal:  Neurotherapeutics       Date:  2021-09-21       Impact factor: 7.620

Review 6.  Short- and Long-Lived Autoantibody-Secreting Cells in Autoimmune Neurological Disorders.

Authors:  C Zografou; A G Vakrakou; P Stathopoulos
Journal:  Front Immunol       Date:  2021-06-17       Impact factor: 7.561

Review 7.  Autoantibodies Against the Node of Ranvier in Seropositive Chronic Inflammatory Demyelinating Polyneuropathy: Diagnostic, Pathogenic, and Therapeutic Relevance.

Authors:  Atay Vural; Kathrin Doppler; Edgar Meinl
Journal:  Front Immunol       Date:  2018-05-14       Impact factor: 7.561

8.  Antibodies to neurofascin, contactin-1, and contactin-associated protein 1 in CIDP: Clinical relevance of IgG isotype.

Authors:  Andrea Cortese; Raffaella Lombardi; Chiara Briani; Ilaria Callegari; Luana Benedetti; Fiore Manganelli; Marco Luigetti; Sergio Ferrari; Angelo M Clerici; Girolama Alessandra Marfia; Andrea Rigamonti; Marinella Carpo; Raffaella Fazio; Massimo Corbo; Anna Mazzeo; Fabio Giannini; Giuseppe Cosentino; Elisabetta Zardini; Riccardo Currò; Matteo Gastaldi; Elisa Vegezzi; Enrico Alfonsi; Angela Berardinelli; Ludivine Kouton; Constance Manso; Claudia Giannotta; Pietro Doneddu; Patrizia Dacci; Laura Piccolo; Marta Ruiz; Alessandro Salvalaggio; Chiara De Michelis; Emanuele Spina; Antonietta Topa; Giulia Bisogni; Angela Romano; Sara Mariotto; Giorgia Mataluni; Federica Cerri; Claudia Stancanelli; Mario Sabatelli; Angelo Schenone; Enrico Marchioni; Giuseppe Lauria; Eduardo Nobile-Orazio; Jérôme Devaux; Diego Franciotta
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2019-11-21

9.  Antiparanodal antibodies and IgG subclasses in acute autoimmune neuropathy.

Authors:  Luise Appeltshauser; Anna-Michelle Brunder; Annika Heinius; Peter Körtvélyessy; Klaus-Peter Wandinger; Ralf Junker; Carmen Villmann; Claudia Sommer; Frank Leypoldt; Kathrin Doppler
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2020-07-24

Review 10.  Complement in neurological disorders and emerging complement-targeted therapeutics.

Authors:  Marinos C Dalakas; Harry Alexopoulos; Peter J Spaeth
Journal:  Nat Rev Neurol       Date:  2020-10-01       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.